The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients

Antiviral Therapy

Volumn 10, Issue 2, 2005, Pages 349-355

  Kruse, Guido ^a   Esser, Stefan ^b   Stocker, Hartmut ^c,d   Breske, Antje ^a   Koerber, Andreas ^b   Kopperman, Maija ^b   Wiehler, Heidi ^b   Ross, Birgit ^b   Möcklinghoff, Christiane ^e   Hill, Andrew ^f   Becker, Mark ^g   Kurowski, Michael ^a,d  

^a Therapia GmbH   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Vivantes Auguste Viktoria Klinikum   (Germany)

^d German HIV/AIDS Competence Network   (Germany)

^e Roche ^*  (Germany)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ADENINE; DRUG DERIVATIVE; HYDROXY T BUTYLAMIDENELFINAVIR; HYDROXY-T-BUTYLAMIDENELFINAVIR; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; METABOLISM; MIDDLE AGED; TIME;

ADENINE; ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NELFINAVIR; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

EID: 22844441964     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Pecora FP & Kirian MA. Effect of tenofovir on didanosine absorption in patients with HIV. Annals of Pharmacotherapy 2003; 37:1325-1328.
2. Chapman T, McGavin J & Noble S. Tenofovir disoproxil fumarate. Drugs 2003; 63:1597-1608.
3. Taburet AM, Piketty C, Chazallon C, Vincent I, Gerard L, Calvez V, Clavel F, Aboulker JP & Girard PM. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy 2004; 48:2091-2096.
4. Kearney BP, Mittan A, Sayre J, Flaherty JF, Zhong L, Toole JJ & Cheng AK. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. 14-17 September 2003, Chicago, IL, USA. Abstract A-1617.
5. Saag MS, Tebas P, Sension M, Conant M, Myers R, Chapman SK, Anderson R & Clendeninn N. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS 2001; 15:1971-1978.
6. Petersen A, Antunes F & Arasteh K. A comparison of the long-term antiviral efficacy of BID and TID dosing of nelfinavir in combination with stavudine (d4T) and lamivudine (3TC) beyond 48 weeks. 7th European Conference on Clinical Aspects & Treatment of HIV Infection. 23-27 October 2000, Lisbon, Portugal. Abstract 205.
7. Gathe J, Chu A, Yuen N & Petersen A. Durability of nelfinavir combination therapy after 4 years: 3-year extension data from Agouron Study 511. 8th Conference on Clinical Aspects & Treatment of HIV Infection. 28-31 October 2001, Athens, Greece. Poster LB10.
8. Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T & Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17:2603-2614.
9. Sanne I, Piliero P, Squires K, Thiry A & Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. Journal of Acquired Immune Deficiency Syndromes 2003; 32:18-29.
10. Schurmann D, Gathe J, Sanne I & Wood R. Efficacy and safety of GW433908/RTV once daily in therapy-naive subjects, (the SOLO study): 48 week results. 6th International Congress on Drug Therapy in HIV Infection. 17-21 November 2002, Glasgow, UK. Abstract PL14.4.
11. MacManus S, Yates PJ, Elston RC, White S, Richards N & Snowden W. GW433908/r once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18:651-655.
12. Hall CS, Raines CP, Barnett SH, Moore RD & Gallant JE. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS 1999; 13:1207-1212.
13. Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, Powderly WG & Henry K. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS 1999; 13:F23-F28.
14. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC & Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Annals of Internal Medicine 1999; 131:813-821.
15. Elston RC, Yates P, Tisdale M, Richards N, White S & DeJesus E. GW433908/ritonavir: 48-week results in PI-experienced subjects: a retrospective analysis of virological response based on baseline genotype and phenotype. 15th International AIDS Conference. 11-16 July 2004, Bangkok, Thailand. Abstract MoOrB1055.
16. Kurowski M, Müller M, Arasteh K & Möcklinghoff C. Simultaneous monitoring of five protease inhibitors in HIV-infected patients by LC-tandem mass spectrometry. 39th Interscience Conference on Antimicrobial Agents & Chemotherapy. 26-29 September 1999, San Francisco, CA, USA. Abstract 320.
17. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New England Journal of Medicine 1998; 338:853-860.
18. Viracept® package insert. Pfizer 2004.
19. Skowron G, Leoung G, Kerr B, Dusek A, Anderson R, Beebe S & Grosso R. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998; 12:1243-1244.
20. Viread® prescribing information. Gilead 2004.